[1]郑 茜,刘远婷,丁甜甜,等.消积抑癌方对Lewis肺癌荷瘤小鼠MMP-2的影响[J].陕西中医,2021,(7):844-848.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.007]
　ZHENG Qian,LIU Yuanting,DING Tiantian,et al.Effect of Xiaoji Yi'ai recipe on MMP-2 in Lewis lung cancer bearing mice[J].,2021,(7):844-848.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.007]
点击复制

消积抑癌方对Lewis肺癌荷瘤小鼠MMP-2的影响
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2021年7期
页码:
844-848
栏目:
基础研究
出版日期:
2021-07-09

文章信息/Info

Title:
Effect of Xiaoji Yi'ai recipe on MMP-2 in Lewis lung cancer bearing mice
作者:
郑 茜; 刘远婷; 丁甜甜; 李 慧
(新疆医科大学第七附属医院中医科,新疆 乌鲁木齐830000)
Author(s):
ZHENG Qian; LIU Yuanting; DING Tiantian; LI Hui
(Department of Traditional Chinese Medicine,the Seventh Affiliated Hospital of Xinjiang Medical University,Urumqi 830000,China)
关键词:
肺癌;  消积抑癌方;  小鼠;  肿瘤;  血清基质金属蛋白酶-2;  免疫功能
Keywords:
Lung cancer;  Xiaoji Yi'ai recipe;  Mice;  Tumor;  Serum matrix metalloproteinase-2;  Immune function
分类号:
R 734.2
DOI:
DOI:10.3969/j.issn.1000-7369.2020.07.007
文献标志码:
A
摘要:
目的:探讨消积抑癌方对Lewis肺癌荷瘤小鼠MMP-2的影响。方法:建立Lewis肺癌荷瘤小鼠模型,随机分为空白组、荷瘤组、消积抑癌方内服组、消积抑癌方外敷组、消积抑癌方内服联合外敷组。观察各组Lewis肺癌荷瘤小鼠肿瘤体积、癌重、抑癌率,对比各组免疫器官重量及血清基质金属蛋白酶-2(MMP-2)、血管内皮生长因子(VEGF)、缺氧诱导因子-1α(HIF-1α)、干扰素(IFN)-γ、IL-10、TNF-α、IL-2水平。结果:第7天、第14天、第21天及第30天,联合组Lewis肺癌荷瘤小鼠肿瘤体积、癌重、抑癌率均明显低于荷瘤组、内服组、外敷组; 内服组、外敷组Lewis肺癌荷瘤小鼠肿瘤体积、癌重、抑癌率均明显低于荷瘤组,差异具有统计学意义(P<0.05); 空白组、联合组脾脏指数、胸腺指数与荷瘤组、内服组、外敷组比较,差异有统计学意义(P<0.05); 空白组、联合组MMP-2、VEGF、HIF-1α、IFN-γ、IL-10、TNF-α、IL-2水平比较,差异有统计学意义(P<0.05); 内服组、外敷组MMP-2、VEGF、HIF-1α、IFN-γ、IL-10、TNF-α、IL-2水平与荷瘤组、空白组比较,差异有统计学意义(P<0.05); 荷瘤组MMP-2、VEGF、HIF-1α、IFN-γ、IL-10、TNF-α、IL-2水平与空白组比较,差异有统计学意义(P<0.05)。结论:消积抑癌方内服联合外敷能够有效抑制Lewis肺癌荷瘤小鼠体内肿瘤,降低MMP-2水平,调节机体免疫功能。
Abstract:
Objective:To explore the effect of Xiaoji Yi'ai recipe on MMP-2 in mice bearing Lewis lung cancer.Methods: Lewis lung cancer tumor-bearing mouse model were established and randomly divided into a blank group,a tumor-bearing group,Xiaoji Yi'ai recipe orally taken group,Xiaoji Yi'ai recipe external application group,Xiaoji Yi'ai recipe orally combined with external application group.Observed the tumor volume,cancer weight and tumor suppressor rate of each group of Lewis lung cancer tumor-bearing mice,compare the weight of immune organs and MMP-2,VEGF,and HIF-1α,IFN-γ,IL-10,TNF-α,IL-2 levels.Results:On day 7,14,21 and 30,the tumor volume,cancer weight,and tumor suppression rate of Lewis lung cancer bearing mice in the combined group were significantly lower than those in the tumor-bearing group,oral administration group,and external application group.The tumor volume,cancer weight and tumor suppression rate of Lewis lung cancer bearing mice in the external application group were significantly lower than those in the tumor bearing group,and the difference was statistically significant(P<0.05).The spleen index and thymus index of the blank group and the combined group were compared with the tumor-bearing group,the oral administration group,and the external application group,and the difference was statistically significant(P<0.05),the spleen index and thymus index of the internal administration group,the external application group and the tumor-bearing group and the blank group The difference was statistically significant(P<0.05).the spleen index and thymus index of the tumor-bearing group were compared with the blank group,and the difference was statistically significant(P<0.05).Comparison of the levels of MMP-2,VEGF,HIF-1α,IFN-γ,IL-10,TNF-α,IL-2 between the blank group and the combination group was statistically significant(P<0.05).the MMP of the oral and external application group MMP-2,VEGF,HIF-1α,IFN-γ,IL-10,TNF-α,IL-2 levels compared with tumor-bearing group and blank group,the difference was statistically significant(P<0.05).tumor-bearing group MMP- 2.Compared with the blank group,the levels of VEGF,HIF-1α,IFN-γ,IL-10,TNF-α,and IL-2 were statistically significant(P<0.05).Conclusion:The oral administration of Xiaoji Yi'ai recipe combined with external application can effectively inhibit tumors in mice bearing Lewis lung cancer,reduce the level of MMP-2,and regulate the immune function of the body.

参考文献/References:

[1] Nasim F,Sabath BF,Eapen GA.Lung cancer[J].Med Clin North Am,2019,103(3):463-473.
[2] Hoy H,Lynch T,Beck M.Surgical treatment of lung cancer[J].Crit Care Nurs Clin North Am,2019,31(3):303-313.
[3] 陈敬生,胡中保,严龙君,等.参麦注射液联合化疗对晚期非小细胞肺癌生存质量的影响[J].陕西中医,2018,39(3):298-300.
[4] 贾 方,王秋月,崔文静,等.金复康口服液对Lewis肺癌荷瘤小鼠PD-1、PD-L1表达及相关免疫因子的影响[J].陕西中医,2020,41(10):1347-1350,1417.
[5] 李白坤,湛宇灿,李庆林,等.中医药治疗肺癌作用机制研究进展[J].安徽中医药大学学报,2018,37(3):90-93.
[6] 陈 奇.中药药理研究方法学[M].3版.北京:人民卫生出版社,2011:33-34.
[7] 兰 俊.黄芪注射液加玻璃酸钠注射液关节腔内注射治疗膝骨关节炎临床研究[J].中医正骨,2009,21(10):746-751.
[8] 关雅素,刘 洋,吕 鹏.益气养阴解毒方治疗肺癌患者EGFR-TKIs相关皮疹的临床观察[J].世界中西医结合杂志,2020,15(3):142-145.
[9] 张荣芹,魏品康.益气除痰方联合顺铂治疗肺癌疗效及对患者生存质量、Akt/FoxO信号通路的影响[J].陕西中医,2018,39(12):1698-1701.
[10] 李赛凯,骆莹滨,吴建春,等.益气扶正方对Lewis肺癌小鼠抑瘤作用的实验研究[J].中华中医药学刊,2017,35(3):569-572.
[11] 孙国钧,张蕴萍,宋 静,等.益气消征方对Lewis荷瘤小鼠肿瘤抑制及免疫调节影响的实验研究[J].辽宁中医药大学学报,2019,187(11):42-45.
[12] 张素芳,向卉楠,王丽新,等.培元固本方抑制肺癌荷瘤小鼠肿瘤生长并延长生存期的实验研究[J].世界中医药,2019,14(8):2004-2009.
[13] Chen X,Ai X,Wu C,et al.A novel human IL-2 muteinwith minimal systemic toxicity exerts greater antitumor efficacy than wild-type IL-2[J].Cell Death Dis,2018,9(10):989.
[14] 白鹏飞,张艳君,李 敏.荆芥连翘汤加减从肺论治溃疡性结肠炎疗效及对患者肠黏膜屏障功能、免疫调节、氧化应激指标的影响[J].陕西中医,2020,41(7):897-900.
[15] Liu W,Chen X,He Y,et al.TNF-αinhibits xenograft tumor formation by A549 lung cancer cells in nude micevia the HIF-1α/VASP signaling pathway[J].Oncol Rep,2019,41(4):2418-2430.
[16] Jafari-Nedooshan J,Moghimi M,Zare M,et al.Association of promoter regionpolymorphisms of IL-10 gene with susceptibility to lung cancer:System aticre view and meta-analysis[J].Asian Pac J Cancer Prev,2019,20(7):1951-1957.
[17] Rataj F,Kraus FBT,Chaloupka M,et al.PD1-CD28 fusion protein enables CD4+T cell help foradoptive cell therapy in models of pancreatic cancer and non-hodgkin lymphoma[J].Front Immunol,2018,30(9):1955.
[18] Byun Y,Choi YC,Jeong Y,et al.MiR-200c downregulates HIF-1αand inhibits migration of lung cancer cells[J].Cell Mol Biol Lett,2019,27(24):28-30.
[19] Chen Y,Mathy NW,Lu H.The role of VEGF in the diagnosis and treatment ofmalignant pleural effusion in patients with non-small cell lung cancer(Review)[J].Mol Med Rep,2018,17(6):8019-8030.
[20] Cui J,Yin Z,Liu G,et al.Activating transcription factor 1 promoted migration and invasion in lung cancer cellsthrough regulating EGFR and MMP-2[J].Mol Carcinog,2019,58(10):1919-1924.

相似文献/References:

[1]刘海涛 ,衣秀秀,田建辉△.肺癌中西医抗凝治疗研究进展*[J].陕西中医,2020,(1):127.
[2]邵翠丽,周晋华△,杨勤军,等.周晋华运用环磷酰胺联合中药紫杉治疗晚期肺癌经验*[J].陕西中医,2020,(2):223.
　SHAO Cuili,ZHOU Jinhua,YANG Qinjun,et al.ZHOU Jinhua treats advanced lung cancer with cyclophosphamide and purple shirt[J].,2020,(7):223.
[3]汪 莉,杜红旭,周正国,等.攻癌固真汤联合吉非替尼治疗肺癌气虚血瘀证疗效及对患者血流状态的影响[J].陕西中医,2021,(3):338.[doi:DOI:10.3969/j.issn.1000-7369.2020.03.017]
　WANG Li,DU Hongxu,ZHOU Zhengguo,et al.Clinical effect of Gong'ai Guzhen decoction combined with gefitinib in treating lung cancer with Qixu Xueyu syndrome and affect blood flow state[J].,2021,(7):338.[doi:DOI:10.3969/j.issn.1000-7369.2020.03.017]
[4]刘文佳,刘宗凯,初晓苏,等.山慈菇-王不留行干预肺癌向骨转移过程生物信息学作用机制[J].陕西中医,2021,(9):1302.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.041]
[5]杨 昕,李和根.肺癌辨证分型研究进展[J].陕西中医,2021,(9):1313.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.043]
　YANG Xin,LI Hegen.Progress in syndrome differentiation of lung cancer[J].,2021,(7):1313.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.043]
[6]李 健,贾 瑞,王 超,等.健脾益气汤联合化疗对肺癌术后患者免疫功能的影响[J].陕西中医,2023,(4):459.[doi:DOI:10.3969/j.issn.1000-7369.2023.04.011]
　LI Jian,JIA Rui,WANG Chao,et al.Effect of Jianpi Yiqi decoction combined with chemotherapy on immune function in patients with lung cancer after surgery[J].,2023,(7):459.[doi:DOI:10.3969/j.issn.1000-7369.2023.04.011]
[7]宁永波,王雅兴,陈香颖,等.名中医王瑞平“期证相合”理论在肺癌术后研究肿瘤微环境经验[J].陕西中医,2023,(10):1448.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.026]
　NING Yongbo,WANG Yaxing,CHEN Xiangying,et al.Wang Ruiping's theory of “phase correspondence” in postoperative lung cancer patients[J].,2023,(7):1448.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.026]
[8]张 尤,陈 炜.名中医韩明向基于“一本四证”论治肺癌经验[J].陕西中医,2023,(12):1788.[doi:DOI:10.3969/j.issn.1000-7369.2023.12.027]
[9]陈香颖,宁永波,王雅兴,等.名中医王瑞平运用“培土生金法”治疗肺癌经验[J].陕西中医,2024,(4):536.[doi:DOI:10.3969/j.issn.1000-7369.2024.04.023]
　CHEN Xiangying,NING Yongbo,WANG Yaxing,et al.Experience of professor Wang Ruiping using “tonifying the spleen and replenishing the lung” to treat lung cancer[J].,2024,(7):536.[doi:DOI:10.3969/j.issn.1000-7369.2024.04.023]
[10]王 倩,蒋思雨,刘倩希,等.加味麦门冬汤联合安罗替尼治疗晚期驱动基因阴性非小细胞肺癌临床疗效[J].陕西中医,2024,(8):1048.[doi:DOI:10.3969/j.issn.1000-7369.2024.08.008]
　WANG Qian,JIANG Siyu,LIU Qianxi,et al.Clinical efficacy of modified Maimendong decoction combined with anlotinib on advanced driver gene-negative non-small cell lung cancer[J].,2024,(7):1048.[doi:DOI:10.3969/j.issn.1000-7369.2024.08.008]

备注/Memo

备注/Memo:
基金项目:新疆维吾尔自治区自然科学基金资助项目(2018D01C242)
更新日期/Last Update: 2021-07-07